SMAD3 and renal cell carcinoma: Targeting ERβ/TGFβ1/SMAD3 signals with selective estrogen receptor modulators (e.g. a FDA‐approved anti‐estrogen, Faslodex, or an ERβ selective antagonist, PHTPP) could help in the development of new therapies to better treat RCC patients.